Magellan Health Competitors

Magellan Health (NASDAQ:MGLN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Magellan Health and Jazz Pharmaceuticals, as reported by MarketBeat.

Magellan Health currently has a consensus target price of $93.3333, suggesting a potential downside of 1.29%. Jazz Pharmaceuticals has a consensus target price of $201.0667, suggesting a potential upside of 16.05%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Magellan Health.

Institutional and Insider Ownership

96.5% of Magellan Health shares are owned by institutional investors. Comparatively, 92.0% of Jazz Pharmaceuticals shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by insiders. Comparatively, 4.8% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Magellan Health and Jazz Pharmaceuticals' top-line revenue, earnings per share and valuation.

Magellan Health has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Magellan Health has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Magellan Health and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats Magellan Health on 9 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Magellan Health (NASDAQ:MGLN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

52.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 96.5% of Magellan Health shares are owned by institutional investors. 0.7% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 14.1% of Magellan Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teva Pharmaceutical Industries and Magellan Health's gross revenue, earnings per share and valuation.

Magellan Health has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Teva Pharmaceutical Industries and Magellan Health, as reported by MarketBeat.com.

Teva Pharmaceutical Industries presently has a consensus target price of $11.25, suggesting a potential upside of 25.84%. Magellan Health has a consensus target price of $93.3333, suggesting a potential downside of 1.29%. Given Teva Pharmaceutical Industries' higher probable upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Magellan Health.

Profitability

This table compares Teva Pharmaceutical Industries and Magellan Health's net margins, return on equity and return on assets.

Volatility & Risk

Teva Pharmaceutical Industries has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Summary

Teva Pharmaceutical Industries beats Magellan Health on 8 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Natera (NASDAQ:NTRA) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Magellan Health and Natera's net margins, return on equity and return on assets.

Risk & Volatility

Magellan Health has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Magellan Health and Natera, as provided by MarketBeat.com.

Magellan Health currently has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Natera has a consensus price target of $128.7273, suggesting a potential upside of 16.45%. Given Natera's stronger consensus rating and higher probable upside, analysts plainly believe Natera is more favorable than Magellan Health.

Institutional and Insider Ownership

96.5% of Magellan Health shares are held by institutional investors. Comparatively, 96.0% of Natera shares are held by institutional investors. 14.1% of Magellan Health shares are held by company insiders. Comparatively, 10.9% of Natera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Magellan Health and Natera's gross revenue, earnings per share (EPS) and valuation.

Magellan Health has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Summary

Magellan Health beats Natera on 9 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and Magellan Health (NASDAQ:MGLN) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

Penumbra has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Magellan Health has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Profitability

This table compares Penumbra and Magellan Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for Penumbra and Magellan Health, as reported by MarketBeat.com.

Penumbra currently has a consensus price target of $310.40, suggesting a potential upside of 18.43%. Magellan Health has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Given Penumbra's stronger consensus rating and higher possible upside, equities research analysts clearly believe Penumbra is more favorable than Magellan Health.

Institutional & Insider Ownership

84.0% of Penumbra shares are owned by institutional investors. Comparatively, 96.5% of Magellan Health shares are owned by institutional investors. 7.5% of Penumbra shares are owned by insiders. Comparatively, 14.1% of Magellan Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Penumbra and Magellan Health's gross revenue, earnings per share and valuation.

Magellan Health has higher revenue and earnings than Penumbra. Magellan Health is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Magellan Health beats Penumbra on 9 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Risk & Volatility

Magellan Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Magellan Health and Intellia Therapeutics, as provided by MarketBeat.

Magellan Health presently has a consensus price target of $93.3333, suggesting a potential downside of 1.29%. Intellia Therapeutics has a consensus price target of $122.0625, suggesting a potential downside of 8.91%. Given Magellan Health's higher probable upside, research analysts clearly believe Magellan Health is more favorable than Intellia Therapeutics.

Profitability

This table compares Magellan Health and Intellia Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Magellan Health and Intellia Therapeutics' revenue, earnings per share and valuation.

Magellan Health has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.5% of Magellan Health shares are held by institutional investors. Comparatively, 91.9% of Intellia Therapeutics shares are held by institutional investors. 14.1% of Magellan Health shares are held by company insiders. Comparatively, 4.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Magellan Health beats Intellia Therapeutics on 10 of the 14 factors compared between the two stocks.

Magellan Health (NASDAQ:MGLN) and Syneos Health (NASDAQ:SYNH) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional & Insider Ownership

96.5% of Magellan Health shares are owned by institutional investors. Comparatively, 91.4% of Syneos Health shares are owned by institutional investors. 14.1% of Magellan Health shares are owned by company insiders. Comparatively, 0.3% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Magellan Health has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Syneos Health has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Magellan Health and Syneos Health, as reported by MarketBeat.com.

Magellan Health currently has a consensus target price of $93.3333, indicating a potential downside of 1.29%. Syneos Health has a consensus target price of $86.60, indicating a potential downside of 0.74%. Given Syneos Health's stronger consensus rating and higher probable upside, analysts clearly believe Syneos Health is more favorable than Magellan Health.

Profitability

This table compares Magellan Health and Syneos Health's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Magellan Health and Syneos Health's top-line revenue, earnings per share and valuation.

Magellan Health has higher revenue and earnings than Syneos Health. Syneos Health is trading at a lower price-to-earnings ratio than Magellan Health, indicating that it is currently the more affordable of the two stocks.

Summary

Syneos Health beats Magellan Health on 9 of the 14 factors compared between the two stocks.